Our Cases

Compass Lexecon has been involved in many of the largest and most complex antitrust litigation and financial market cases over the past 30 years.

Find a Case

Sorry, your search didn't return any results.

03/18/19

In March 2019, the European Commission ("EC") closed its investigation into the licensing practices of a number of Hollywood studios and large European pay-TV broadcasters (Case AT.40023 'Cross-border access to pay-TV', initiated in January 2014) after the parties accepted legally...

05/18/17

In May 2017, the European Commission approved the $7.4 billion acquisition of Baker Hughes by General Electric (GE) without remedies after a Phase I investigation. The newly formed BHGE combined the digital solutions and technology from GE with Baker Hughes'...

12/23/16

Compass Lexecon advised the State Oil Company of Azerbaijan Republic (SOCAR) during the Phase II merger investigation by the European Commission of SOCAR's acquisition of DESFA, the natural gas transmission operator in Greece, which was privatized as part of Greece's...

08/16/16

Compass Lexecon experts provided economic advice to Apple Inc. during the European Commission’s State aid inquiry against Ireland (Opening Decision of 11 June 2014). The European Commission investigated whether decisions taken by tax authorities in Ireland, with regard to corporate...

07/22/16

In July 2016, the European Commission ("EC") approved the transaction by which EPH, a Slovakian energy Group, acquired a controlling share in Sloveske Elektrane (“SE”) from Enel SpA for €375 million. SE is the successor to the former state monopoly...

05/22/16

Compass Lexecon advised Baker Hughes during its proposed $28 billion merger with rival oilfield services provider, Halliburton. The acquisition of Baker Hughes by Halliburton would have combined the world's number two and number three oil service companies. The parties abandoned...

02/01/16

In February 2016, the UK Competition & Markets Authority (CMA) fined Actavis and other pharmaceutical companies in the context of its investigation of ‘reverse payments’ in the Paroxetine market. The investigation focused on whether payments from GlaxoSmithKline to IVAX, Generics...

01/21/15

In January 2015, the European Commission cleared the $13 billion (£9.2 billion) transaction between GlaxoSmithKline (GSK) and Novartis, subject to conditions, after a Phase I investigation. The transaction involved (a) the transfer of Novartis' human vaccines to GSK; (b) a...